"10.1371_journal.pone.0127063","plos one","2015-05-11T00:00:00Z","Derek C Marshall; Susan K Lyman; Scott McCauley; Maria Kovalenko; Rhyannon Spangler; Chian Liu; Michael Lee; Christopher O’Sullivan; Vivian Barry-Hamilton; Haben Ghermazien; Amanda Mikels-Vigdal; Carlos A Garcia; Brett Jorgensen; Arleene C Velayo; Ruth Wang; Joanne I Adamkewicz; Victoria Smith","Department of Biology, Gilead Sciences, Inc., Foster City, California, United States of America; Department of Process Development, Gilead Sciences, Inc., Oceanside, California, United States of America","Conceived and designed the experiments: DM SL SM MK ML CO CG VS. Performed the experiments: DM SL SM MK RS CL ML CO VB HG AM CG BJ AV RW. Analyzed the data: DM SL SM MK RS CL ML CO VB HG AM CG BJ AV RW. Wrote the paper: DM SL JA VS.","The authors have the following interests: All authors are current or former employees of Gilead Sciences. This study was funded by Gilead Sciences. Gilead Sciences holds the patent ‘Antibodies to matrix metalloproteinase 9’ (US8501916 B2) and the patent application ‘Antibodies to matrix metalloproteinase 9’ (US20130281676 A1), and is currently evaluating the humanized monoclonal antibody GS-5745 in Phase 1 clinical trials (ClinicalTrials.gov identifiers NCT01831427, NCT02077465, and NCT01803282). None of these competing interests affect the authors adherence to PLOS ONE policies regarding the sharing of data and materials associated with the submitted manuscript.","2015","05","Derek C Marshall","DCM",17,TRUE,8,15,15,4,TRUE,TRUE,FALSE,0,NA,FALSE
